An assessment of statin safety by muscle experts.
The National Lipid Association's (NLA) Muscle Safety Expert Panel was charged with the duty of examining the definitions, causative factors, and management of statin myopathy. The Panel was asked to use its evidence-based findings to form recommendations in response to a series of specific questions posed by the Task Force. The panel was composed of a clinical cardiologist, an exercise physiologist and skeletal muscle expert, and an expert in preventive cardiology who also examined skeletal muscle complications of statin use.
Thompson
Paul D
PD
Division of Cardiology, Hartford Hospital, Hartford, Connecticut 06102, USA. pthomps@harthosp.org
Clarkson
Priscilla M
PM
Rosenson
Robert S
RS
D001706:Biopsy; D003402:Creatine Kinase / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004348:Drug Labeling; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D018482:Muscle, Skeletal / Q000473:pathology; D009135:Muscular Diseases / Q000139:chemically induced* / Q000145:classification / Q000517:prevention & control
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D003402:Creatine Kinase